Glaucoma remains one of the most common causes of vision loss and blindness in the U.S. and much of the world, disproportionately affecting older people, African Americans, and Hispanics and Latinos. Early signs of glaucoma can vary, from eye pressure to changes in the appearance of the optic nerve, and the disease can progress for
New research at ACR Convergence 2023, the American College of Rheumatology’s (ACR) annual meeting, shows that patients with refractory juvenile systemic sclerosis improved significantly on nearly all measures for two years following autologous stem cell transplant (Abstract #L06). Juvenile-onset systemic sclerosis (jSSc), also called scleroderma, is a disfiguring autoimmune disorder marked by hardening of the skin
Researchers at the University of Leicester have discovered the mechanism by which cholesterol in our diet is absorbed into our cells. This discovery, which has just been published in the journal Science opens up new opportunities for therapeutic intervention to control cholesterol uptake that could complement other therapies and potentially save lives. The research, conducted with colleagues
A broken bone failing to heal represents an enormous burden for patients, which also often leads to further additional surgeries being required. Fraunhofer researchers have worked alongside partners to develop a composite material to be used in the treatment of such non-union cases. The resulting implant (termed scaffold) is designed to significantly improve treatment success
Undetectable levels achieved for nearly nine months in phase 1 trial A novel short-interfering RNA (siRNA) therapy known as lepodisiran reduced levels of lipoprotein(a) (Lp(a)) below the lowest limit of quantitation for nearly nine months in a first-in-human phase 1 trial. The study, presented by Steven Nissen, MD, in a late-breaking science session at the American
A single infusion of a CRISPR-based gene editing therapy significantly reduced LDL-C and PCSK9 levels in patients with heterozygous familial hypercholesterolemia (HeFH), based on findings from the VERVE-101 trial presented Nov. 12 at AHA 2023. In presenting the findings, Andrew Bellinger, MD, PhD, said they provide the first proof-of-concept for in vivo DNA base editing in humans.
Semaglutide 2.4 mg (Wegovy®) cardiovascular outcomes data presented at American Heart Association Scientific Sessions and simultaneously published in New England Journal of Medicine At the American Heart Asoociation annual Scientific Session were announced the primary results of SELECT, its landmark phase 3 cardiovascular outcomes trial investigating the effects of once-weekly semaglutide 2.4 mg (Wegovy®) in
Millions of people with normal blood pressure may be misclassified as having blood pressure that is too high because of improper positioning when measurements are taken, new research suggests. Guidelines from the American Heart Association and American College of Cardiology call for a patient to be seated in a chair with feet flat on the
Scientists have long sought to understand how certain animals, such as zebrafish, are able to regrow nerve fibers and regain lost motor function after spinal cord injury. In humans, these injuries are irreparable and result in permanent loss of function, such as paralysis. An international team led by Daniel Wehner of the Max Planck Institute
The work of the COVID Moonshot Consortium is being published in the prestigious journal Science on 10 November, revealing their discovery of a potent SARS-CoV-2 antiviral lead compound. It also reflects on the success of its open science approach in launching a patent-free antiviral discovery program to rapidly develop a differentiated lead in response to
